Excitatory and inhibitory lateral interactions effects on contrast detection are modulated by tRNS.

Contrast sensitivity for a Gabor signal is affected by collinear high-contrast Gabor flankers. The flankers reduce (inhibitory effect) or increase (facilitatory effect) sensitivity, at short (2λ) and intermediate (6λ) target-to-flanker separation respectively. We investigated whether these inhibitory/facilitatory sensitivity effects are modulated by transcranial random noise stimulation (tRNS) applied to the occipital and frontal cortex of human observers during task performance. Signal detection theory was used to measure sensitivity (d') and the Criterion (C) in a contrast detection task, performed with sham or tRNS applied over the occipital or the frontal cortex. After occipital stimulation results show a tRNS-dependent increased sensitivity for the single Gabor signal of low but not high contrast. Moreover, results suggest a dissociation of the tRNS effect when the Gabor signal is presented with the flankers, consisting in a general increased sensitivity at 2λ where the flankers had an inhibitory effect (reduction of inhibition) and a decreased sensitivity at 6λ where the flankers had a facilitatory effect on the Gabor signal (reduction of facilitation). After a frontal stimulation, no specific effect of the tRNS was found. We account for these complex interactions between tRNS and flankers by assuming that tRNS not only enhances feedforward input from the Gabor signal to the cortex, but also enhances the excitatory or inhibitory lateral intracortical input from the flankers. The boosted lateral input depends on the excitation-inhibition (E/I) ratio, namely when the lateral input is weak, it is boosted by tRNS with consequent modification of the contrast-dependent E/I ratio.

Prostate-specific antigen as a unique routine test in monitoring therapy for inoperable prostate cancer: comparison with radionuclide bone scan and prostatic acid phosphatase.

The aim of the present investigation was the evaluation of cost-effectiveness of variables used in monitoring patients with inoperable prostate cancer. Prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), and radionuclide bone scan were considered. The tumor marker positivity was assessed according to dynamic criteria (> 50% increase between consecutive samples). 108 patients entered the study; 72 patients treated with a luteinizing hormone-releasing hormone analogue were followed up for periods ranging from 12 to 64 months. PSA and PAP levels were measured using immunometric assays. Both cutoff-based and dynamic, serial sample-based decision criteria were employed. With respect to a positive bone scan, PSA showed negative predictive values of 82 and 77%, respectively, using 4 and 10 ng/ml as cutoff points. Progression of the disease to the bone occurred in 20 patients: in 17 PSA was the first indicator of progression, in the other 3 PAP anticipated PSA for a very short time (3-4 months), which was not of relevance to clinical decisions. PAP is less specific and sensitive than PSA; PAP may eventually provide information on disease status in a limited percentage of patients with advanced prostate cancer treated with androgen ablation, being differently regulated with respect to PSA. No increasing PSA profile was detected in patients who responded to the therapy. From the results of the present investigation, we draw the following conclusions: (1) PSA can be used reliably as a unique tool in the follow-up of patients for the early detection of progressive disease, and (2) dynamic criteria of evaluation of serial PSA determinations probably provide more effective and earlier clinical information.

Relationship between prostatic acid phosphatase and prostate-specific antigen serum levels and prostatic volume in benign prostate hyperplasia. Pitfall on tumor markers assessment in primary prostatic cancer?

Serum levels of prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA) were measured in 78 patients with benign prostate hyperplasia and compared with both the gland weight and the glandular component of prostatic tissue. Both PAP and PSA were significantly higher where prostate was heavier; however, we could not find a consistent factor which could correlate weight increase to marker levels. PSA tended to be higher when glandular component was more expressed. From the present findings we conclude that in patients with prostate cancer, PAP and PSA serum levels should be investigated considering also the benign components of prostate gland.